# Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of SB2 in Healthy Subjects

> **NCT01922336** · PHASE1 · COMPLETED · sponsor: **Samsung Bioepis Co., Ltd.** · enrollment: 159 (actual)

## Conditions studied

- Healthy

## Interventions

- **BIOLOGICAL:** SB2
- **BIOLOGICAL:** EU Remicade
- **BIOLOGICAL:** US Remicade

## Key facts

- **NCT ID:** NCT01922336
- **Lead sponsor:** Samsung Bioepis Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-07
- **Primary completion:** 2013-10
- **Final completion:** 2013-10
- **Target enrollment:** 159 (ACTUAL)
- **Last updated:** 2019-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01922336

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01922336, "Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of SB2 in Healthy Subjects". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01922336. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*